Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

FairJourney Bio and AbTherx partner to offer fully integrated antibody discovery

24

Jun 2026

FairJourney Bio and AbTherx partner to offer fully integrated antibody discovery

FairJourney Bio (“FJBio”), a global antibody discovery expert, has entered a partnership with AbTherx, Inc. to bring transgenic mouse-based antibody discovery in-house. The agreement gives the Company access to AbTherx’s Atlas™ Full Human Diversity (FHD) and Common Light Chain (cLC) mouse technologies, completing a discovery route that partners can now run end to end entirely within FJBio’s integrated workflow.

Human-AI teams improve healthcare only when clinicians stay in control

24

Jun 2026

Human-AI teams improve healthcare only when clinicians stay in control

A scoping review of 140 empirical studies found that human-AI collaboration in healthcare reports the most consistent benefits in diagnostic interpretation, especially when AI supports bounded tasks and clinicians retain final responsibility. Evidence remains fragmented across triage, treatment planning, and documentation, with few studies measuring patient outcomes, system impact, trust calibration, or governance in real-world settings.

Lost weight is less likely to return when exercise follows obesity treatment

24

Jun 2026

Lost weight is less likely to return when exercise follows obesity treatment

A systematic review and meta-analysis of 11 randomized controlled trials found that exercise during the post-weight-loss maintenance phase reduced weight regain by an average of 2.81 kg compared with control groups. Evidence for fat-mass reduction remained inconclusive, highlighting the need for longer, standardized trials with better adherence and body-composition monitoring.

Early diabetes drug treatment links to better survival after diagnosis thresholds

24

Jun 2026

Early diabetes drug treatment links to better survival after diagnosis thresholds

A Korean target trial emulation found that starting antidiabetic medication within 12 months of newly crossing type 2 diabetes diagnostic thresholds was associated with lower five-year all-cause mortality. MACE risk was numerically lower with earlier treatment, but the reductions in cardiovascular events were not statistically significant, underscoring the need for larger studies.

Strength training plus cardio cuts type 2 diabetes risk the most

23

Jun 2026

Strength training plus cardio cuts type 2 diabetes risk the most

A 20-year prospective cohort study of 143,715 US healthcare professionals found that long-term resistance training was associated with a substantially lower risk of type 2 diabetes. The lowest risk was seen among participants who combined regular resistance training with adequate aerobic activity and limited TV viewing.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.